Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-11-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于调整2020年限制性股票激励计划授予价格的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding an adjustment to the grant price of its 2020 restricted stock incentive plan. It details board and supervisory meetings, approvals, legal opinions, and the rationale for adjusting the stock grant price due to dividend distribution. The document is a formal disclosure about a change in the stock incentive plan terms, not a full annual report, audit report, or earnings release. It is not a proxy solicitation or voting result announcement, nor is it a management report or investor presentation. The content fits best under a regulatory announcement category related to corporate governance and stock incentive plan adjustments. Given the specificity and nature of the announcement, it aligns with Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories. The document length is under 5,000 characters and is a standalone announcement, not a report publication announcement. Therefore, the classification is RNS with high confidence.
2021-11-15 Chinese
美迪西：2021年第二次临时股东大会会议资料
AGM Information Classification · 100% confidence The document is titled "2021 年第二次临时股东大会会议资料" which translates to "2021 Second Extraordinary General Meeting (EGM) Meeting Materials". It contains detailed agenda items, meeting instructions, candidate biographies for board and supervisory committee elections, and procedural rules for the shareholder meeting. The content is focused on the materials prepared for the shareholders to review and discuss during the meeting, including proposals for amendments to company bylaws and election of directors and supervisors. There are no financial statements or earnings data, nor is this a transcript or announcement of voting results. The document is clearly the meeting materials provided for the shareholders ahead of or during the EGM. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. The document length (9376 characters) and detailed content confirm it is the meeting materials themselves, not just an announcement or summary.
2021-11-12 Chinese
美迪西：独立董事关于第二届董事会第二十次会议相关事项的独立意见
Regulatory Filings
2021-11-05 Chinese
美迪西：关于修订《公司章程》及《公司监事会议事规则》的公告
Governance Information Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding revisions to the company's Articles of Association and Supervisory Board Meeting Rules. It details specific changes in the number of supervisors and the election process for the chairman of the supervisory board. The document is a formal announcement of governance-related changes and does not contain financial data, audit information, or detailed reports. It is not a full report but an announcement about governance documents and their amendments, which aligns with Governance Information filings. The document is short (923 characters) and focuses on internal governance rules, so the appropriate classification is Governance Information (CGR).
2021-11-05 Chinese
美迪西：独立董事提名人声明（马大为、赖卫东、许金叶）
Regulatory Filings
2021-11-05 Chinese
美迪西：公司章程（2021年修订）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Shanghai Medicilon Inc. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and other governance matters. It is a foundational governance document that sets out the internal rules and regulations of the company. There is no indication that this is an annual report, financial report, or any announcement related to voting results or management changes. The content aligns with the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2021-11-05 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.